Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI.

ABSTRACT:

Background

Antimicrobial resistance is an emerging problem.

Hypothesis/objective

To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment.

Animals

Six healthy research dogs; nine client-owned dogs with recurrent UTI.

Methods

Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 10¹⁰ CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation.

Results

No LUTS were noted in any of th

SUBMITTER: Segev G 

PROVIDER: S-EPMC5787194 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature